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AbstrAct
Introduction Patients require an accurate knowledge 
about placebos and their possible effects to ensure 
consent for placebo-controlled clinical trials is adequately 
informed. However, few previous studies have explored 
patients’ baseline (ie, pretrial recruitment) levels of 
understanding and knowledge about placebos. The 
present online survey aimed to assess knowledge about 
placebos among patients with a history of back pain.
Design A 15-item questionnaire was constructed 
to measure knowledge about placebos. Additional 
questions assessed sociodemographic characteristics, 
duration and severity of back pain, and previous 
experience of receiving placebos.
setting Participants recruited from community settings 
completed the study online.
results 210 participants completed the questionnaire. 
86.7% had back pain in the past 6 months, 44.3% 
currently had back pain. 4.3% had received a placebo 
intervention as part of a clinical trial and 68.1% had 
previously read or heard information about placebos. 
Overall knowledge of placebos was high, with 
participants on average answering 12.07 of 15 questions 
about placebos correctly (SD=2.35). However, few 
participants correctly answered questions about the 
nocebo effect (31.9% correct) and the impact of the 
colour of a placebo pill (55.2% correct).
conclusions The findings identified key gaps in 
knowledge about placebos. The lack of understanding of 
the nocebo effect in particular has implications for the 
informed consent of trial participants. Research ethics 
committees and investigators should prioritise amending 
informed consent procedures to incorporate the fact that 
participants in the placebo arm might experience adverse 
side effects.
IntroDuctIon
Placebos are an essential component of randomised 
controlled trials (RCTs). They are used to control 
for bias, contextual and psychological components 
of treatment and thus isolate the speciﬁc effects of 
the intervention under investigation. Administering 
placebos to patients can elicit both beneficial and 
adverse (‘nocebo’) effects. Many factors are now 
known to impact on the strength of the placebo 
response, including factors associated with the 
healthcare professional administering treatment, 
the patient receiving treatment and their thera-
peutic relationship.1–4 Characteristics of the inter-
vention itself, such as medication colour, the form 
and frequency of administration also influence the 
strength of placebo response.5–8 Nocebo effects 
are typically linked to patient expectations derived 
from side-effect warnings and can be conditioned 
from previous adverse events.9 Common nocebo 
effects include nausea, stomach pains, itching, 
bloating, depression and sleep problems.10
It is important that potential trial participants 
know about placebo and nocebo effects. At minimum 
an accurate knowledge of the possible benefits and 
adverse effects of placebos is necessary to ensure 
consent to take part in an RCT is adequately 
informed. In addition, people’s understanding of, 
and attitudes towards, placebos may influence their 
willingness to participate in placebo-controlled 
RCTs11 12 and thus could have implications for fair 
access. However, information leaflets used in RCTs 
often provide incomplete or inaccurate information 
about placebos. Bishop et al found that only 1 of 45 
participant  information leaflets used in major RCTs 
in the UK mentioned that placebos may elicit bene-
ficial effects and only four mentioned that placebos 
can elicit adverse effects.13
It is necessary to assess people’s baseline knowl-
edge of placebos (ie, before participating in any trial 
recruitment activities) in order to identify common 
gaps in knowledge and thus specify the placebo 
characteristics that should be prioritised for inclu-
sion in participant information leaflets. However, 
little is known about the public’s knowledge of 
placebos and placebo effects. We surveyed people 
with back pain to examine current levels of placebo 
knowledge and identify knowledge gaps. To the 
authors’ knowledge this is the first such study. The 
objective was to inform improvements to informed 
consent procedures.
MethoDs
Design and measures
A web-based cross-sectional survey was conducted. 
Fifteen true-false items assessed knowledge of 
placebos (for items, see table 1). Items were devel-
oped after consulting with experts in placebo 
research and examining relevant literature. The 
questionnaire was pretested with 10 lay volun-
teers and modified based on their feedback. The 
survey also assessed demographic characteristics; 
experience of/sources of knowledge about placebos 
(to permit an initial assessment of the validity of 
our knowledge questionnaire); and history and 
severity of back pain and its impact on daily living, 
using the validated reliable Chronic Pain Grade 
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Questionnaire.14 Participants also completed a 15-item acupunc-
ture questionnaire (reported separately15).
Participants
We surveyed adults with a history of back pain, as back pain is 
prevalent16 and placebos have demonstrated pronounced effects 
in chronic pain conditions.17
Procedure
Ethical approval was given by the University of Southampton 
Psychology Ethics Committee.
Fifteen UK universities invited staff and students to partici-
pate via email. The study was also advertised on social media 
sites pertaining to back pain and to local businesses. Adults 
who had ‘had back pain’ were invited to take part in a ‘short 
(10 min) online quiz’ about alternative treatments for back 
pain. On clicking a link participants reached an information 
page presenting study details and a tick-box to indicate consent. 
Participants then completed the survey.
Data were imported into SPSS V.22 and summarised using 
descriptive statistics. Analysis of variance, t-test, χ2 test and Spear-
man’s correlation test assessed whether knowledge of placebos 
was related to previous experience of receiving placebos, having 
read or heard about placebos, gender, age, ethnicity, highest 
qualification and back pain characteristics.
results
Participant characteristics
Two hundred and twenty-six people participated between July 
and October 2014. Data were excluded from 16 individuals 
who failed to complete any placebo knowledge items, leaving 
210 participants. One hundred and thirty-six participants were 
female (67.7%) and 65 were male (32.3%), aged 18–74 years 
(M=35, SD=14.05) (9 skipped these items). All participants 
reported back pain: 100% ever had back pain, 86.7% (n=182) 
in the past 6 months and 44.3% (n=93) currently. Of those 
reporting current back pain, average pain intensity was mild 
(M=3.4, SD=2.16) (see table 2 for additional characteristics).
experiences of placebos
Only nine participants (4.3%) had previously received a placebo 
as part of an RCT, but 68.1% (n=143) reported having previ-
ously read or heard about placebos, via friends and family, 
school/university, general knowledge, books, media and/or the 
internet.
Knowledge
Participants answered between 4 and 15 knowledge items 
correctly (M=12.07; SD=2.35) (see table 1). Key gaps in 
placebo knowledge were identified; 31.9% knew that a placebo 
pill can have side effects and 55.2% knew that the colour of a 
placebo pill can change how effective it is.
The nine participants who had previously received placebo 
treatment as part of an RCT (M=12.22, SD=1.64) had similar 
knowledge scores to the 201 who had not (M=12.06, SD=2.39) 
(p=0.841). However, the 143 participants who reported previ-
ously reading or hearing about placebos had significantly higher 
scores (M=12.55, SD=2.15) than the 67 who indicated they 
had not read or heard about placebos (M=10.97, SD=2.49) 
(t=4.663, df=205, p<0.001).
There were just two differences in knowledge by sociodemo-
graphic and clinical characteristics. Participants who identified 
as white British had higher placebo knowledge scores than other 
ethnicities combined (M=12.47 (SD=2.18) and M=11.33 
(SD=2.50), respectively; t=3.422, df=208, p=0.001). Partic-
ipants who reported less intense pain during the previous 
table 1 Participants’ knowledge about placebos
Item
correct 
answer total % correct (n)
read/heard about placebos 
(n=143)† % correct (n)
not read/heard about placebos 
(n=64)† % correct (n)
A pill with aspirin in it is called a ‘placebo’ pill False 98.1% (206) 98.6% (141) 96.9% (62)
The placebo effect can work because of people’s expectations True 95.2% (200) 99.3% (142) 85.9% (55)**
Placebo treatments are only effective for people who are not very 
intelligent
False 96.7% (203) 97.9% (140) 93.8% (60)
Placebo treatments can help to treat pain conditions True 79.5% (167) 82.5% (118) 71.9% (46)
Placebo treatments do not help to relieve any medical symptoms False 72.9% (153) 76.2% (109) 65.6% (42)
Placebo pain treatments only relieve imaginary pain (ie, pain that 
was not real in the first place)
False 85.2% (179) 89.5% (128) 75.0% (48)**
A pill with no medicine in it is called a ‘placebo’ pill True 91.9% (193) 97.9% (140) 78.1% (50)**
The placebo effect can work because of conditioning True 74.3% (156) 74.8% (107) 73.4% (47)
Real changes in the brain can occur when you receive a placebo (such 
as the release of chemicals called opioids)
True 83.8% (176) 88.1% (126) 73.4% (47)*
Placebo effects are imaginary and have no real physical effects on 
our body
False 81.0% (170) 83.2% (119) 76.6% (49)
Placebo effects only occur in experiments and research trials False 86.2% (181) 90.2% (129) 76.6% (49)**
A placebo pill can have side effects True 31.9% (67) 34.3% (49) 28.1% (18)
The placebo effect can help us to get better during normal medical 
treatments
True 79.5% (167) 83.9% (120) 68.8% (44)*
The colour of a placebo pill can change how effective it is True 55.2% (116) 60.1% (86) 43.8% (28)*
Placebo treatments are only effective for people who lie about their 
symptoms
False 96.7% (203) 99.3% (142) 90.6% (58)**
*p<0.05, **p<0.01, significant χ2.
†Three participants did not specify whether they had previously read or heard about placebos.
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6 months had higher placebo knowledge scores than those who 
reported more intense pain (rs=−0.210; p<0.01).
DIscussIon
Placebos are an important component of RCTs used to elucidate the 
speciﬁc effects of an intervention under investigation. For informed 
consent to be valid, trial participants need an accurate knowledge 
of placebos; this should minimally include an understanding that 
placebos can have both beneficial and adverse effects.18 Our commu-
nity-based survey of people with back pain found relatively high 
knowledge overall but only a small minority of participants knew 
that placebos could have adverse, that is, nocebo, effects. Evidence 
from meta-analysis suggests as many as 52% of RCT participants 
receiving a placebo may experience nocebo effects.19 However, just 
31.9% of our participants knew that a placebo can have side effects. 
Earlier studies elsewhere reported similar findings: 4.8% of general 
practitioner patients in New Zealand agreed that placebos can cause 
bad side effects20 and 7.7% of patients recruited from a rheumatology 
clinic  in France believed placebos can induce adverse effects.21 Our 
study updates and extends this work, suggesting that the UK patients 
would also benefit from receiving information about nocebo effects 
before taking part in a placebo-controlled RCT.
A lack of placebo knowledge among potential trial partici-
pants has implications for the ethical principle of autonomy, 
and consequently participants’ ability to provide full informed 
consent. Respect for autonomy requires potential participants to 
have sufficient information to enable them to make an informed 
decision regarding participation. In particular, the Declaration of 
Helsinki18 requires volunteers to be informed about the poten-
tial benefits and harms of participation. The knowledge gaps 
identified within the present study, combined with the limited 
descriptions of placebos in participant information sheets found 
previously,13 suggest that in many cases participants do not have 
an adequate understanding of the potential benefits and harms 
of placebos before consenting to placebo-controlled RCTs. This 
would appear to violate the principle of autonomy, and may 
question the ethical validity of consent.22
There is increasing awareness that ethical practices, such as the 
content of participant information sheets, should be grounded in 
empirical data.23 24 However, there remains a dearth of published 
research to inform investigators and research ethics committees. 
This study was strengthened by using evidence-based items to 
assess placebo knowledge objectively. The fact that participants 
who had previously read or heard about placebos scored higher 
than other participants provides initial evidence for the construct 
validity of the knowledge questionnaire.
Selection bias is a limitation; participants were more highly 
educated than the general UK population (almost 50% possessed 
a postgraduate qualification). This may have driven the high 
placebo knowledge scores and a more representative sample 
might have exhibited less knowledge; indeed, even lower levels 
of knowledge about nocebo effects have been reported by 
others.20 21 However, educational attainment was not related to 
placebo knowledge in this sample.
Research ethics committees and investigators should prioritise 
amending informed consent documentation and procedures to 
explain that participants in the placebo arm might experience 
beneficial and adverse effects. Our findings suggest that while 
volunteers may have some existing knowledge that placebos can 
elicit beneficial effects, they are far less likely to appreciate their 
potential to elicit adverse effects. Adding information about 
nocebo effects to participant information sheets and associated 
discussions might therefore increase participants’ capacity to 
provide ethically valid informed consent. Future research could 
evaluate placebo knowledge gaps in other patient groups and 
develop resources and guidelines to improve the provision of 
patient information about placebo and nocebo effects. In the 
meantime, we recommend that research ethics committees apply 
greater scrutiny to the description of placebos in participant 
information sheets.
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table 2 Participant characteristics
number (n) Per cent (%)
  Gender*
  Female 136 67.7
  Male 65 32.3
Ethnic origin
  White British 137 65.2
  Other White background 39 18.6
  Asian or Asian British 9 4.3
  Chinese 7 3.3
  Other 16 7.7
  Preferred not to state ethnicity 2 1.0
Occupation
  Student 66 31.4
  Administrator/secretary 27 12.9
  Academic 25 11.9
  Postgraduate student 21 10.0
  Researcher 19 9.0
  Teaching 12 5.7
  Healthcare professional 8 3.8
  Currently not working/retired 7 3.3
  Technician/programmer 7 3.3
  Care work 4 1.9
  Engineering 2 1.0
  Other 12 5.7
Highest level of education
  Secondary school 10 4.8
  Some college 31 14.8
  Bachelor’s degree 50 23.8
  Master’s degree 58 27.6
  Doctoral degree 44 21.0
  Other 17 8.1
Pain in past 6 months† Mean sD
  Intensity 4.23 1.96
  Interference in daily activities 3.83 2.57
  Interference in recreational activities 3.08 2.70
  Interference in work activities 2.93 2.61
*Nine participants did not specify their gender.
†Items answered on a 0–10 scale, where 10 indicates highest levels of pain 
intensity/interference.
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